Login to Your Account

Merck turns up heat: immunotherapy trio of deals disclosed

By Randy Osborne
Staff Writer

Thursday, February 6, 2014

Merck & Co. Inc.’s minor slip in its latest earnings wrap-up was offset by news of three separately done deals to combine the company’s prized immunotherapy MK-3475 in various phase I/II trials with cancer drugs from Amgen Inc., Incyte Corp. and Pfizer Inc. – arrangements intended to help Merck gain ground against the likes of Bristol-Myers Squibb Co. (BMS) in the anti-PD-1 space by getting access to unpartnered cancer assets by way of research pacts.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription